NetworkNewsBreaks – Zenosense, Inc.’s (ZENO) M
Post# of 53
Through a joint-venture ownership in MIDS Medical Ltd., Zenosense (OTC: ZENO) is developing MIDS Cardiac™, a rapid cardiac diagnostic device. An article discussing the device reads: “In the new testing, the joint venture aimed to magnetically detect assay beads below the 200,000 level in order to support a finding that the technology could be effective in a high-sensitivity troponin test. Previously, the technology had detected down to around 100,000 beads; the new testing brings this down to around the 50,000-bead level, indicating that it is well within the necessary level of detection required for a high-sensitivity assay (http://nnw.fm/MlnX9). The new testing used extensively improved core sensor electronics to deliver the near-doubling of the previously obtained sensitivity level.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer